Is SNAP-8 the same as Botox?

No. SNAP-8 is a topical cosmetic ingredient that targets the same molecular pathway (SNARE complex / SNAP-25) that botulinum toxin affects, but the analogy ends there. Botulinum toxin is a pharmaceutical injected directly into muscle tissue, producing reliable, dose-dependent paralysis. SNAP-8 is applied to the skin surface; whether it reaches neuromuscular junctions in meaningful concentrations through the skin barrier has not been independently confirmed. Any anti-wrinkle effects observed in small studies are modest compared to injectable botulinum toxin.

Can SNAP-8 be injected?

No. SNAP-8 is formulated and evaluated exclusively as a topical cosmetic ingredient. There is no safety data, dosing protocol, or regulatory basis for injectable use. Injecting a cosmetic ingredient carries serious and unpredictable risks. It should be used only as intended — applied to skin.

How do I reconstitute SNAP-8 and mix it into a serum or cream?

For skincare, dissolve SNAP-8 powder into a water-based carrier such as a hyaluronic-acid serum — not bacteriostatic water, which contains benzyl alcohol you should not apply to the face daily. A common starting point is about 10 mg per 30 ml of serum or cream (roughly 0.03%), raised toward ~20 mg per 30 ml to taste; start low because you can add more but cannot remove it. Add it to a cool, finished base, preserve any water-based blend with a broad-spectrum preservative, store it in an amber bottle in the fridge, and use it within about 28 days. Patch test first. This is cosmetic-formulation reference, not medical advice.

What does the clinical evidence actually show?

The strongest available data come from a manufacturer-sponsored split-face study using a cream with approximately 0.05% acetyl octapeptide-3, applied twice daily for 28 days, which found wrinkle depth reduced by up to 38% (average 7.1%). Larger figures (up to 63%) cited in marketing originate from internal testing rather than peer-reviewed publications. Multi-ingredient serum studies that included SNAP-8 showed wrinkle improvements, but effects cannot be isolated to SNAP-8 alone. Independent, adequately powered trials have not been published.

What concentration should SNAP-8 be used at in a cosmetic formula?

Manufacturer guidance and cosmetic formulation community sources suggest 4–10 ppm of active SNAP-8 in the finished product, typically achieved by adding a stock solution (often 0.05% or higher) at 1–3% of the formula. This is a cosmetic formulation figure, not a medical dose. Follow the technical data sheet provided by the ingredient supplier.

Is SNAP-8 regulated or approved?

SNAP-8 (acetyl octapeptide-3) is permitted as a cosmetic ingredient under the EU Cosmetics Regulation and is used in cosmetic products in the United States, where it is regulated by the FDA as a cosmetic, not a drug. It has not been approved by any regulatory authority as a drug treatment for wrinkles or any other medical condition. The CIR Expert Panel has reviewed related acetylated peptides and has not identified significant safety concerns at cosmetic use concentrations.

Does SNAP-8 penetrate the skin deeply enough to work?

This is an open scientific question. Research on the structurally similar acetyl hexapeptide-8 (Argireline) found less than 0.2% of applied peptide penetrated the stratum corneum after 24 hours, and authors of a 2025 review concluded that delivery to neuromuscular junctions through standard topical application is likely impossible. Whether SNAP-8 behaves similarly, or whether advanced delivery systems (liposomes, microneedle patches) meaningfully improve penetration, remains an active research area. Observable improvements in wrinkle appearance may involve surface hydration or texture effects alongside — or instead of — the proposed neuromuscular mechanism.

Aesthetic

SNAP-8

Also known as: Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-1, Acetyl-EEMQRRAD-NH2

Topical cosmetic peptide (acetyl octapeptide-3) for serums/creams - never injected. An Argireline relative for expression lines; evidence is mostly manufacturer data.

Reviewed by the Helica Labs research team · Last updated August 10, 2026

Buy SNAP-8

Overview

SNAP-8 is a synthetic eight-amino-acid peptide derived from the N-terminal sequence of SNAP-25 (synaptosomal-associated protein 25), a component of the SNARE complex involved in vesicle-mediated neurotransmitter release. It was developed by Lipotec S.A. (Barcelona, Spain) as a topical cosmetic active under the INCI name Acetyl Octapeptide-3, and it is classified in most markets — including the EU and the United States — as a cosmetic ingredient, not a pharmaceutical drug. SNAP-8 is structurally related to Argireline (acetyl hexapeptide-3/acetyl hexapeptide-8), which targets the same SNAP-25 binding site using a six-amino-acid fragment. SNAP-8 extends that chain by two residues, and its developer claims greater potency as a result, though independent head-to-head data are limited. Both peptides are marketed as topical alternatives to injectable botulinum toxin, though the analogy is mechanistic rather than clinical: the amounts and tissue depths achievable through topical application differ fundamentally from an intramuscular injection. The evidence base for SNAP-8 consists predominantly of in-vitro mechanistic work and small manufacturer-sponsored clinical studies. Independent, peer-reviewed, adequately powered trials are lacking. The most commonly cited figure — up to 63% reduction in wrinkle depth over 28 days — comes from manufacturer-funded testing. A split-face study using a cream containing 3% of a 0.05% Acetyl Octapeptide-3 solution applied twice daily for 28 days found wrinkle depth lowered by up to 38%, with an average decrease of 7.1%. These results should be interpreted cautiously given the small sample sizes and industry sponsorship typical of cosmeceutical ingredient research. A key biological uncertainty is skin penetration. Related data on acetyl hexapeptide-8 — the closest well-studied analogue — show that less than 0.2% of topically applied peptide penetrates the stratum corneum after 24 hours, and whether any fraction reaches the neuromuscular junction in biologically meaningful concentrations remains unconfirmed. If wrinkle improvements are observed in humans, epidermal-level effects (hydration, surface texture) may contribute alongside the proposed neuromuscular mechanism. SNAP-8 is used exclusively as a topical cosmetic ingredient and should not be reconstituted for injection.

How it works

SNAP-8 is a biomimetic fragment of SNAP-25, one of the three core SNARE proteins that drive synaptic vesicle docking and neurotransmitter release at the neuromuscular junction. By presenting a competing N-terminal SNAP-25 sequence, the peptide is proposed to interfere with SNARE complex assembly, partially reducing the exocytotic release of acetylcholine and other neurotransmitters. Reduced neurotransmitter release is expected to decrease the frequency or magnitude of facial muscle contraction, thereby diminishing the mechanical repetition that deepens dynamic expression lines (forehead furrows, crow's feet, glabellar lines) over time. The key limitation of this mechanism when applied topically is delivery: the stratum corneum is a significant barrier for hydrophilic peptides of this size (~1,075 Da), and published data on the closely related acetyl hexapeptide-8 indicate extremely low transdermal penetration under standard cream conditions. Whether SNAP-8 reaches the dermis or neuromuscular junction in concentrations sufficient to meaningfully inhibit SNARE complex assembly through topical application alone has not been independently confirmed. Alternative or complementary explanations — including surface hydration effects and texture improvements at the epidermal level — have not been ruled out by clinical studies to date.

Researched effects

Clinical Reduces depth of expression wrinkles (forehead lines, crow's feet) after repeated topical application over 28 days
Preclinical Inhibits SNARE complex assembly and reduces neurotransmitter release in cell-based models
Clinical May improve overall appearance of fine lines and skin texture as part of a multi-ingredient cosmetic formulation
Preclinical Comparable or superior wrinkle-reducing effect to acetyl hexapeptide-3 (Argireline) at equivalent topical concentrations

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

SNAP-8 is a cosmetic ingredient, not a pharmaceutical drug, and no clinical dosing protocol exists. Manufacturer-sponsored studies have used formulations containing 3% of a 0.05% acetyl octapeptide-3 solution (equating to roughly 4–10 ppm active peptide in the final product), applied twice daily for 28 days to the periorbital or forehead area. Commercial cosmetic products typically contain 4–10 ppm SNAP-8 in the finished formulation. There is no established therapeutic dose and no regulatory-approved use in any drug indication.

Community-reported dosing (anecdotal)

TOPICAL USE ONLY — SNAP-8 is a skincare active, never injected (it is sold as powder or a freeze-dried puck; neither form is for injection). Reconstituting it for skincare: do NOT use bacteriostatic water (it contains benzyl alcohol you should not apply to the face daily) — instead dissolve the powder directly into a water-based carrier, most commonly a hyaluronic-acid serum. A common community starting point is roughly 10 mg of SNAP-8 per 30 ml of serum or cream (about 0.03%), tested for tolerance and raised toward ~20 mg per 30 ml if desired; some formulators go higher (around 100 mg per 30 ml of HA). Start low — you can always add more, but you cannot remove it once mixed. SNAP-8 pairs well with GHK-Cu, hyaluronic acid, niacinamide and vitamin C. Do's: prefer cosmetic-grade SNAP-8 (lyophilised injection vials can contain fillers); dissolve it fully into a cool, finished base; store it in a light-protecting amber dropper bottle in the fridge; preserve any water-based blend with a broad-spectrum preservative; patch test; a few drops go a long way. Don'ts: never inject it or apply it to broken skin; don't dose it with bacteriostatic/benzyl-alcohol water for facial use; don't over-dilute it (it thins the serum) or assume more is better (higher levels mainly raise irritation risk); don't expose it to heat. Use a reconstituted product within about 28 days for best potency. This is cosmetic-formulation reference, not medical advice.

Half-life: Not applicable in the conventional pharmacological sense. SNAP-8 is a topical cosmetic ingredient; it does not enter systemic circulation in measurable amounts at cosmetic use concentrations. Its residence time on or in the skin is formulation-dependent and has not been formally characterized.
Routes: topical

Safety & side effects

SNAP-8 is a topical cosmetic ingredient only. It is not intended for injection, oral ingestion, or any systemic route of administration. At cosmetic use concentrations (4–10 ppm in finished formulation), it has a favorable safety record with no reports of serious adverse events in published literature or regulatory safety databases. The most commonly noted effects are mild and transient: occasional skin tingling, temporary redness, or dryness, particularly at higher concentrations in sensitive individuals. A patch test before full application is advisable. The Cosmetic Ingredient Review (CIR) safety assessment covering acetyl hexapeptide-8 and related acetylated peptides (including acetyl octapeptide-3) does not identify significant safety concerns at concentrations used in cosmetics. SNAP-8 is not classified as a drug by the FDA, EMA, or equivalent regulatory bodies and has no established pharmaceutical safety profile for non-topical use. Injectable use would be entirely outside any evaluated safety data and should not be attempted. People with known peptide or ingredient sensitivities should consult a dermatologist before use.

Research summary

SNAP-8 (acetyl octapeptide-3) has a plausible molecular rationale: it mimics a segment of SNAP-25 and has been shown in cell-based systems to interfere with SNARE complex assembly, the machinery governing neurotransmitter-driven muscle contraction. The mechanistic hypothesis is coherent, though extrapolating from in-vitro chromaffin cell or neuronal models to topical wrinkle reduction in intact human skin is a significant step. The clinical evidence consists almost entirely of small, manufacturer-sponsored studies. The most referenced trial — a split-face study of a cream containing roughly 0.05% acetyl octapeptide-3 — reported up to 38% reduction in wrinkle depth (average 7.1%) after 28 days of twice-daily application. Higher reduction figures (up to 63%) cited widely online appear to originate from Lipotec internal testing rather than peer-reviewed publications, and independent replication has not been published. A 2023 study of a peptide complex serum that included acetyl octapeptide-3 alongside other actives reported clinically meaningful improvements in wrinkle severity and fine-line visibility over 12 weeks, but the multi-ingredient design prevents attribution of effect to SNAP-8 specifically. A fundamental unresolved question is skin penetration. Research on the structurally analogous acetyl hexapeptide-8 (Argireline) — the closest peer-reviewed proxy — found less than 0.2% transdermal penetration after 24 hours, with delivery to neuromuscular junctions described as 'likely impossible' through standard topical vehicles. Whether delivery systems (liposomes, microneedles, W/O/W emulsions) can overcome this barrier for SNAP-8 remains an active area of research rather than an established finding. Overall, SNAP-8 is among the better-supported cosmetic neuropeptides for anti-wrinkle claims when compared to most topical ingredients, but the evidence base remains limited by industry sponsorship, small sample sizes, and unresolved penetration questions. It should be regarded as a cosmetically active ingredient with a plausible mechanism and supportive but not definitive clinical data — not as a validated drug therapy for wrinkles.

FAQ

Is SNAP-8 the same as Botox?: No. SNAP-8 is a topical cosmetic ingredient that targets the same molecular pathway (SNARE complex / SNAP-25) that botulinum toxin affects, but the analogy ends there. Botulinum toxin is a pharmaceutical injected directly into muscle tissue, producing reliable, dose-dependent paralysis. SNAP-8 is applied to the skin surface; whether it reaches neuromuscular junctions in meaningful concentrations through the skin barrier has not been independently confirmed. Any anti-wrinkle effects observed in small studies are modest compared to injectable botulinum toxin.
Can SNAP-8 be injected?: No. SNAP-8 is formulated and evaluated exclusively as a topical cosmetic ingredient. There is no safety data, dosing protocol, or regulatory basis for injectable use. Injecting a cosmetic ingredient carries serious and unpredictable risks. It should be used only as intended — applied to skin.
How do I reconstitute SNAP-8 and mix it into a serum or cream?: For skincare, dissolve SNAP-8 powder into a water-based carrier such as a hyaluronic-acid serum — not bacteriostatic water, which contains benzyl alcohol you should not apply to the face daily. A common starting point is about 10 mg per 30 ml of serum or cream (roughly 0.03%), raised toward ~20 mg per 30 ml to taste; start low because you can add more but cannot remove it. Add it to a cool, finished base, preserve any water-based blend with a broad-spectrum preservative, store it in an amber bottle in the fridge, and use it within about 28 days. Patch test first. This is cosmetic-formulation reference, not medical advice.
What does the clinical evidence actually show?: The strongest available data come from a manufacturer-sponsored split-face study using a cream with approximately 0.05% acetyl octapeptide-3, applied twice daily for 28 days, which found wrinkle depth reduced by up to 38% (average 7.1%). Larger figures (up to 63%) cited in marketing originate from internal testing rather than peer-reviewed publications. Multi-ingredient serum studies that included SNAP-8 showed wrinkle improvements, but effects cannot be isolated to SNAP-8 alone. Independent, adequately powered trials have not been published.
What concentration should SNAP-8 be used at in a cosmetic formula?: Manufacturer guidance and cosmetic formulation community sources suggest 4–10 ppm of active SNAP-8 in the finished product, typically achieved by adding a stock solution (often 0.05% or higher) at 1–3% of the formula. This is a cosmetic formulation figure, not a medical dose. Follow the technical data sheet provided by the ingredient supplier.
Is SNAP-8 regulated or approved?: SNAP-8 (acetyl octapeptide-3) is permitted as a cosmetic ingredient under the EU Cosmetics Regulation and is used in cosmetic products in the United States, where it is regulated by the FDA as a cosmetic, not a drug. It has not been approved by any regulatory authority as a drug treatment for wrinkles or any other medical condition. The CIR Expert Panel has reviewed related acetylated peptides and has not identified significant safety concerns at cosmetic use concentrations.
Does SNAP-8 penetrate the skin deeply enough to work?: This is an open scientific question. Research on the structurally similar acetyl hexapeptide-8 (Argireline) found less than 0.2% of applied peptide penetrated the stratum corneum after 24 hours, and authors of a 2025 review concluded that delivery to neuromuscular junctions through standard topical application is likely impossible. Whether SNAP-8 behaves similarly, or whether advanced delivery systems (liposomes, microneedle patches) meaningfully improve penetration, remains an active research area. Observable improvements in wrinkle appearance may involve surface hydration or texture effects alongside — or instead of — the proposed neuromuscular mechanism.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.